• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Beyaz - Contraceptive Containing a Folate Approved

Medically reviewed by Drugs.com

MONDAY, Sept. 27 -- Beyaz, a combination estrogen/progestin contraceptive that also contains a folate, has been approved by the U.S. Food and Drug Administration.

The folate, levomefolate calcium, is a B-vitamin that's among a class of vitamins recommended for women of childbearing age. Lack of dietary folate has been associated with neural tube birth defects, which involve deformities of the fetal brain or spinal cord. The newly approved drug is designed to help prevent this type of defect among mothers who conceive shortly after discontinuing the drug, the FDA said in a news release.

Beyaz was studied in a multi-center U.S. trial involving 379 women aged 18 to 40. The most frequently reported side effects included uterine bleeding, nausea, breast tenderness and headache. Other serious side effects included blood clots and liver disease, the FDA said.

Women 35 or older should not use Beyaz, which could increase their risk of "serious cardiovascular events," the agency said.

Beyaz is based on the already approved contraceptive YAZ, which includes the same amounts of estrogen and progestin, the FDA said.

The newly approved drug is produced by Bayer HealthCare Pharmaceuticals.

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted September 2010

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.